ACTRN12619001649101已完成未知
A longitudinal feasibility study exploring cancer related cognitive impairment in patients with newly diagnosed aggressive lymphoma undergoing standard chemotherapy with curative intent.
A/Prof Eliza Hawkes0 个研究点目标入组 30 人开始时间: 2019年11月26日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •1. Age greater than or equal to 18 years
- •2. Newly diagnosed aggressive lymphoma that requires standard chemotherapy treatment with curative intent at Austin Health. Including:
- •Hodgkin lymphoma
- •Diffuse large B cell lymphoma
- •Burkitt lymphoma
- •Transformed follicular lymphoma
- •Grade 3b follicular lymphoma
- •3. Able to read and comprehend English instructions.
- •4. Eastern Collaborative Oncology Group (ECOG) performance status less than or equal to 2
排除标准
- •1. Central Nervous System (CNS) lymphoma
- •2. Prior/planned cranial radiotherapy
- •3. An expected life expectancy < 12 months
- •4. Medical conditions that may compromise compliance or lead to prolonged hospitalisation
- •5. Documented history of or current substance abuse
- •6. Concurrent poorly controlled psychiatric illness.
研究者
相似试验
招募中
不适用
A prospective cohort study on incidence of cancer in patients with pancreatic cystic lesionspancreatic cystic lesionsJPRN-UMIN000007633Okayama University500
进行中（未招募）
1 期
Study to evaluate long-term safety of nivolumab alone or in combination with other cancer therapies.pan tumorMedDRA version: 20.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004362-34-PLBristol-Myers Squibb International Corporation1,231
进行中（未招募）
1 期
Study to evaluate long-term safety of nivolumab alone or in combination with other cancer therapies.pan tumorMedDRA version: 20.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004362-34-ATBristol-Myers Squibb International Corporation1,231
进行中（未招募）
1 期
Study to evaluate long-term safety of nivolumab alone or in combinationwith other cancer therapies.EUCTR2018-004362-34-HUBristol-Myers Squibb International Corporation1,231
进行中（未招募）
1 期
Study to evaluate long-term safety of nivolumab alone or in combination with other cancer therapies.pan tumorMedDRA version: 20.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004362-34-DEBristol-Myers Squibb International Corporation1,231